160 related articles for article (PubMed ID: 23441953)
1. Whole field laser Doppler imaging of the microcirculation in psoriasis and clinically unaffected skin.
Hendriks AG; Steenbergen W; Hondebrink E; van Hespen JC; van de Kerkhof PC; Seyger MM
J Dermatolog Treat; 2014 Feb; 25(1):18-21. PubMed ID: 23441953
[TBL] [Abstract][Full Text] [Related]
2. Clearing of psoriasis documented by laser Doppler perfusion imaging contrasts remaining elevation of dermal expression levels of CD31.
Hendriks AG; van de Kerkhof PC; de Jonge CS; Lucas M; Steenbergen W; Seyger MM
Skin Res Technol; 2015 Aug; 21(3):340-5. PubMed ID: 25534374
[TBL] [Abstract][Full Text] [Related]
3. Microcirculatory modifications of psoriatic lesions during topical therapy.
Rosina P; Giovannini A; Gisondi P; Girolomoni G
Skin Res Technol; 2009 May; 15(2):135-8. PubMed ID: 19622121
[TBL] [Abstract][Full Text] [Related]
4. Perfusion Intensity Correlates with Expression Levels of Psoriasis-Related Genes and Proteins.
Hendriks AG; Steenbergen W; Zeeuwen PL; Schalkwijk J; Hondebrink E; Klitsie MA; Schreurs R; van de Kerkhof PC; Seyger MM
Skin Pharmacol Physiol; 2015; 28(6):296-306. PubMed ID: 26361329
[TBL] [Abstract][Full Text] [Related]
5. Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference.
Sandoval LF; Huang KE; Harrison J; Clark A; Feldman SR
Cutis; 2014 Dec; 94(6):304-9. PubMed ID: 25566573
[TBL] [Abstract][Full Text] [Related]
6. Dual wavelength (532 and 633 nm) laser Doppler imaging of plaque psoriasis.
Murray AK; Herrick AL; Moore TL; King TA; Griffiths CE
Br J Dermatol; 2005 Jun; 152(6):1182-6. PubMed ID: 15948979
[TBL] [Abstract][Full Text] [Related]
7. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
Kin KC; Hill D; Feldman SR
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):789-97. PubMed ID: 27089906
[TBL] [Abstract][Full Text] [Related]
8. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
9. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
[TBL] [Abstract][Full Text] [Related]
10. A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
Hashim PW; Nia JK; Terrano D; Goldenberg G; Kircik LH
J Drugs Dermatol; 2017 Aug; 16(8):747-752. PubMed ID: 28809989
[TBL] [Abstract][Full Text] [Related]
11. Response of cutaneous microcirculation to treatment with mometasone furoate in patients with psoriasis.
Stinco G; Lautieri S; Piccirillo F; Valent F; Patrone P
Clin Exp Dermatol; 2009 Dec; 34(8):915-9. PubMed ID: 19486040
[TBL] [Abstract][Full Text] [Related]
12. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks.
Singh S; Reddy DC; Pandey SS
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):61-5. PubMed ID: 10863225
[TBL] [Abstract][Full Text] [Related]
13. Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.
Bovenschen HJ; Erceg A; Van Vlijmen-Willems I; Van De Kerkhof PC; Seyger MM
J Dermatolog Treat; 2007; 18(1):32-9. PubMed ID: 17365265
[TBL] [Abstract][Full Text] [Related]
14. Balance of Treg versus T-effector cells during systemic treatment with adalimumab and topical treatment with calcipotriol-betamethasone dipropionate ointment.
Keijsers RR; Joosten I; Hendriks AG; Koenen HJ; van Erp PE; van de Kerkhof PC
Exp Dermatol; 2015 Jan; 24(1):65-7. PubMed ID: 25355140
[TBL] [Abstract][Full Text] [Related]
15. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris.
Fenton C; Plosker GL
Am J Clin Dermatol; 2004; 5(6):463-78. PubMed ID: 15663344
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: a 6-week bilaterally controlled, investigator-blinded trial.
Patel T; Bhutani T; Busse KL; Koo J
Cutis; 2011 Sep; 88(3):149-54. PubMed ID: 22017069
[TBL] [Abstract][Full Text] [Related]
17. Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
Frieder J; Kivelevitch D; Menter A
Ther Deliv; 2017 Aug; 8(9):737-746. PubMed ID: 28659016
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.
Queille-Roussel C; Rosen M; Clonier F; Nørremark K; Lacour JP
Clin Drug Investig; 2017 Apr; 37(4):355-361. PubMed ID: 27995521
[TBL] [Abstract][Full Text] [Related]
19. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).
Reich K; Zschocke I; Bachelez H; de Jong EMGJ; Gisondi P; Puig L; Warren RB; Ortland C; Mrowietz U;
Br J Dermatol; 2017 Jul; 177(1):197-205. PubMed ID: 28301043
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
Gorelick J; Cantrell W; Kucera K; Veverka KA; Gooding K
J Drugs Dermatol; 2018 Aug; 17(8):880-884. PubMed ID: 30124727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
